Login to Your Account

Clinic Roundup

Monday, December 5, 2011
• Oncolytics Biotech Inc., of Calgary, Alberta, said interim Phase II data showed intravenous administration of Reolysin in combination with Gemzar (gemcitabine, Eli Lilly and Co.) in patients with advanced pancreatic cancer met the study's primary endpoint.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription